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A recombinant human antibody fragment, designated RSV Fab 19, efficiently neutralizes respiratory syncytial virus (RSV).
Here we report the results of our sequence analysis of antibody escape mutants that identified F glycoprotein amino acids
critical for binding of human or murine RSV F-neutralizing antibodies. © 1998 Academic Press
INTRODUCTION
Antibodies specific for respiratory syncytial virus (RSV)
are of importance because of the urgent need to prevent
or treat the severe disease caused by this paramyxovirus
in infants or in persons of any age with underlying car-
diopulmonary disease or immunodeficiency. RSV is the
major cause of serious viral lower respiratory tract ill-
ness in infants and young children throughout the world
(Collins et al., 1996). Experimental studies in rodents and
nonhuman primates have demonstrated that RSV-spe-
cific polyclonal or monoclonal-neutralizing antibodies
can prevent virus infection in the lungs when adminis-
tered before exposure to virus and can effect rapid res-
olution of infection when administered at the height of
infection (Crowe et al., 1994; Hemming et al., 1985; Prince
et al., 1985; Walsh et al., 1984). Recent clinical trials in
high-risk infants and children using pooled human im-
munoglobulin G that contained a high titer of RSV-neu-
tralizing antibodies (RSVIG) for prophylaxis against se-
vere disease have confirmed these experimental obser-
vations (Groothuis et al., 1993). We are developing RSV-
specific neutralizing human monoclonal antibodies
(mAbs) for topical or intramuscular administration that
might overcome the need for intravenous administration
by virtue of the high level of RSV-specific neutralizing
activity of such mAbs (Crowe et al., 1994). It is likely that
two neutralizing mAbs that bind to distinct antigenic sites
on the F glycoprotein of RSV will be required for passive
antibody immunoprophylaxis or immunotherapy of RSV
disease to prevent the emergence in vivo of antibody
escape mutants. We have developed a human RSV an-
tibody fragment, Fab 19, that has high therapeutic RSV-
specific activity in mice (Crowe et al., 1994). This Fab or
a recombinant bivalent IgG molecule that incorporates
this Fab can be used as a component in an RSV antibody
cocktail consisting of two or more mAbs that recognize
distinct antigenic sites. The current study defines an
amino acid residue on the RSV F glycoprotein that is
essential to its binding to the human anti-RSV antibody
fragment Fab 19. Similar information was obtained for a
panel of murine RSV-neutralizing mAbs that had been
isolated previously (Arbiza et al., 1992; Beeler and van
Wyke Coelingh, 1989).
RESULTS AND DISCUSSION
The predicted amino acid changes encoded by the F
gene nucleotide sequence of the murine MARMs that
were neutralized by Fab 19 are shown in Table 1. F gene
nucleotide sequences derived for all three Fab 19
MARMS (designated RSV 4B, RSV 5A, and RSV 5B) were
identical. These viruses contained a single nucleotide
change of A to G at position 6458 in the RSV genome
(position determined in the message sense, from the 39
end of the virus). This nucleotide change is predicted to
encode an amino acid change at position 266 in the F
glycoprotein of isoleucine to methionine. The binding
epitope of RSV Fab 19 most likely includes amino acid
position 266 on the F glycoprotein; however, there is an
alternative possibility that the change at position 266
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causes a conformational alteration of the protein that
abolishes binding of the Fab at a different site that does
not include the amino acid 266. The region of the F
glycoprotein in which amino acid 266 is located is quite
interesting in that all of the MARMs derived by selection
with site A neutralizing murine mAbs were determined to
contain an amino acid substitution between residues
262 and 276. However, MARMs selected by murine
mAbs did not contain a predicted amino acid change at
position 266. Interestingly, Fab 19 neutralizes MARMs
containing a change at nearby amino acid position 262,
272, 275, or 276, but competition analysis had suggested
previously that Fab 19 was directed at a distinct anti-
genic site (Barbas et al., 1992). It is possible that the lack
of competition of the human Fab fragments against
whole mouse immunoglobulin molecules in the compe-
tition binding assay is a function of the smaller size of the
Fab.
Several nucleotide substitutions could result in an
amino acid change at position 266; however, the same
A-to-G substitution was found in three instances. The
reason for this finding is not clear. One possibility is that
a mutant virus was present in the wild-type parent virus
pool at an undetectable level and virus passages in the
presence of Fab enriched for the growth of this mutant,
rather than independently selecting three mutants de
novo during antibody-treated passages.
In summary, we have identified an amino acid residue
on the RSV F glycoprotein that is essential to binding for
the first isolated RSV-neutralizing human mAb. This res-
idue is near other residues important for binding a panel
of murine RSV mAbs. The Fab 19 holds promise as an
important component of an antibody preparation for im-
munoprophylaxis or immunotherapy of RSV disease in
humans (Crowe et al., 1994).
MATERIALS AND METHODS
The human Fab 19, previously cloned from a combi-
natorial phage display library, was expressed in Esche-
richia coli and then purified from crude cell lysates by
immunoaffinity chromatography using an anti-human
Fab antibody as described previously (Barbas et al.,
1992; Crowe et al., 1994). Purified RSV Fab 19 was ana-
lyzed for its ability to neutralize the RSV A2/HEK-7 wild-
type virus (Connors et al., 1995) and each of 11 viruses in
a panel of previously described MARMs selected for
resistance to neutralization by the various murine mAbs
listed in Table 1 (Arbiza et al., 1992; Beeler and van Wyke
Coelingh, 1989). The Fab 19 neutralized the wild-type
TABLE 1
RSV Monoclonal Antibody-Resistant Mutants (MARMs) Selected with the Human Recombinant Fab 19 Contain a Predicted Amino Acid
Change from the Wild-Type Sequence that Differs from Changes Found in Mutants Selected with Murine mAbs
Antibody used to
select MARM
MARM selected with
indicated mAbsa
Mutation in RSV F glycoprotein
Nucleotide Amino acid
Position(s)
Codon change wild-type
A2 3 MARM Position(s)
AA change wild-type
A2 3 MARM
Murine
1237 v1237 839 AAC 3 TAC 276 Asn 3 Tyr
1214 v1214 839 AAC 3 TAC 276 Asn 3 Tyr
1129 v1129 837 TCC 3 TTC 275 Ser 3 Phe
151 v151 829 AAG 3 AAT 272 Lys 3 Asn
1200 v1200 829 AAG 3 AAT 272 Lys 3 Asn
1142 v1142 108 TTT 3 TCT 32 Phe 3 Ser
829 AAG 3 AAT 272 Lys 3 Asn
1153 v1153 798 AAT 3 AGT 262 Asn 3 Ser
1269 v1269 1179 CCC 3 CAC 389 Pro 3 His
1308F v1308F 735 GCA 3 GTA 241 Ala 3 Val
1275 AAA 3 ACA 421 Lys 3 Thr
1302A v1302A 735 GCA 3 GTA 241 Ala 3 Val
1275 AAA 3 AGA 421 Lys 3 Arg
RSV 19b C4848 1298c CGT 3 AGT 429 Arg 3 Ser
Human
Fab 19 4B 811 ATA 3 ATG 266 Ile 3 Met
Fab 19 5A 811 ATA 3 ATG 266 Ile 3 Met
Fab 19 5B 811 ATA 3 ATG 266 Ile 3 Met
a All mutants were derived from the RSV wild-type strain A2.
b The similarity in numerical designation of Fab 19 is fortuitous; the murine mAb 19 is not related to the human Fab 19.
c Previously determined sequence change (Arbiza et al., 1992).
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parent and each of the MARMS with a high level of
specific activity (,1 mg/ml).
Three independently derived MARMs were isolated
from the RSV A2 wild-type virus, each by a separate
passage series in which virus was selected two times by
growth in the presence of the human Fab 19 at a con-
centration of 30 mg/ml, and then amplified by growth in
the absence of Fab 19. Each of three independently
derived virus suspensions derived in this manner was
biologically cloned by three plaque passages. The
MARMs so selected were shown to resist complete
neutralization with Fab 19 in cell culture. For example,
the titer of the RSV A2 wild-type virus was reduced by 5.7
log10 PFU/ml after incubation with 150 mg/ml Fab com-
pared with PBS control, whereas the titer of each of the
Fab 19-selected MARMs was reduced by ,10-fold. The
MARMs were reduced in plaque titer in repeated tests
on average by 3- to 4-fold after incubation with Fab 19
compared with incubation with PBS. It is not known
whether this represents a virus specific effect, but this
reduction falls within the expected range of variability of
the plaque assay.
Viral RNA from each of the MARMs was prepared from
virus-infected LLC-MK2 or HEp-2 cell monolayer cultures
as described (Connors et al., 1995). The RNA was re-
versed transcribed into cDNA and the F protein gene
was amplified by PCR using gene-specific primers,
cloned into a plasmid vector or, in some cases, the
replicative form of phage M13mp19, and sequenced by
the dideoxynucleotide method using either plasmid or
RSV F gene-specific sequencing primers and T7 poly-
merase (Sequenase; U.S. Biochemical, Cleveland, OH)
as described previously (Connors et al., 1995). Consen-
sus sequences were determined by sequencing cDNA
clones derived from at least two independent PCRs.
Differences between the observed sequences and that
of the previously determined parental virus RSV A2/
HEK-7 were confirmed by sequencing two or more
clones in both forward and reverse directions. The pre-
viously described RSV antibody escape mutant C4848
(also designated v324 in the previous publication), which
contains a single nucleotide change in the F glycoprotein
that encodes a predicted amino acid change at amino
acid position 429 from the N-terminus (Arbiza et al.,
1992), was kindly supplied by Dr. Geraldine Taylor (AFRC
Institute for Animal Health, Compton, U.K.).
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